Latus Bio has announced the completion of a $42 million funding round, which will support its efforts to develop a gene therapy for Huntington's disease.
The company is preparing to submit an application to the FDA for approval to initiate a clinical trial focused on this promising treatment.
Huntington's disease, a progressive neurodegenerative disorder, currently has limited treatment options, making advancements in this area particularly significant.